Amid increasing economic tensions with the United States, China recently announced that it would ban Illumina, a U.S.-based company and the ...

The San Diego company also lowered its financial guidance for 2025 in response to China’s import restrictions.

Illumina will seek to cut $100 million in expenses by the end of this fiscal year as it plans to deal with a loss of revenue ...

Illumina, Inc. (NASDAQ:ILMN) offers sequencing- and array-based solutions for genetic and genomic analysis. The one-month return of Illumina, Inc. (NASDAQ:ILMN) was -32.97%, and its shares lost 34 ...

A contrast dye allergic reaction can occur after a diagnostic imaging test, such as magnetic resonance imaging (MRI) or computed tomography (CT) scan. The contrast dye used with these tests is an ...

1μl of total cellular RNA was used for sequencing library generation by NEBNext Ultra RNA Library Prep Kit for Illumina (NEB, USA, Catalog #: E7530L) following manufacturer’s recommendations and index ...

At a launch event on Feb. 20, Roche detailed plans to enter Illumina's sequencing stronghold with a new platform. Roche's platform is in testing now and scheduled to launch commercially in 2026.

BEIJING’S surprise move to blacklist Illumina has unleashed a frenzy among the US firm’s Chinese rivals to win market share from the gene-sequencing giant. While Illumina is still assessing the ...

Founded in 1998, Illumina is a genetic testing company. It develops DNA sequencing and array-based life sciences technologies to enable research discovery. Illumina sells a number of DNA sequencing ...

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...

Illumina Inc (NASDAQ:ILMN)., a leading player in the genomic sequencing industry, finds itself at a critical juncture as it navigates a shifting competitive landscape and global economic challenges.